Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors

被引：0
|
作者：
Tapia, Gonzalo
Lundy, Joanne
Richardson, Gary Edward
Zhao, Niky
Ebsworth, Karen
Yue, Huibin
Miao, Shichang
Degoma, Emil
Jain, Rita
Schall, Thomas J.
Sullivan, Kathleen
Zhang, Penglie
De Souza, Paul L.
机构：
[1] Univ Adelaide, ICON Canc Ctr, Adelaide, SA, Australia
[2] Paso Med, Frankston, Vic, Australia
[3] Cabrini Res, Malvern, Vic, Australia
[4] ChemoCentryx, San Carlos, CA USA
[5] ChemoCentryx Inc, San Carlos, CA USA
[6] Univ Western Sydney, Sch Med, Campbelltown, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2593
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors
    Papadopoulos, K. P.
    Markman, B.
    Tabernero, J.
    Patnaik, A.
    Heath, E. I.
    DeCillis, A.
    Laird, D.
    Aggarwal, S. K.
    Nguyen, L.
    LoRusso, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Preliminary results of a phase I dose escalation study of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced tumors
    Cheng, Xiangdong
    Song, Zhengbo
    Zhang, Jian
    Jin, Jianan
    Gao, Shuiping
    Liu, Rujiao
    Sun, Yuping
    Zhang, Yan
    Gao, Shegan
    Jia, Ruinuo
    Jing, Deqiang
    Xu, Yu
    Zheng, Lina
    Zhao, Xiwen
    Li, Wei
    Lu, Qiying
    Tian, Wenzhi
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] MULTICENTER, DOSE-ESCALATION STUDY OF THE INVESTIGATIONAL DRUG TAK-733, AN ORAL MEK INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: PRELIMINARY PHASE 1 RESULTS
    Adjei, A. A.
    LoRusso, P. M.
    Ribas, A.
    Sosman, J. A.
    Dy, G. K.
    Chmielowski, B.
    Lipman, P.
    Zhou, X.
    Gangolli, E.
    Bozon, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 158 - 158
  • [34] A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.
    Scheulen, M. E.
    Mross, K. B.
    Richly, H.
    Nokay, B.
    Frost, A.
    Scharr, D.
    Lee, K.
    Saunders, O.
    Hilbert, J.
    Fietz, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] A phase I dose-escalation study of the safety and pharmacokinetics of a novel spectrum selective kinase inhibitor, XL820, administered orally to patients with solid tumors
    Papadopoulos, K.
    Rodon, J.
    Mita, A.
    O'Rourke, P.
    Patnaik, A.
    Rubin, E.
    Tolcher, A.
    Stein, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 33 - 33
  • [36] Phase 1 Dose-escalation Study of PF-04449913, an Oral Hedgehog Inhibitor in Patients with Select Solid Tumors
    Wagner, A.
    Messersmith, W.
    Shaik, N.
    Zheng, X.
    McLachlan, K.
    Cesari, R.
    Courtney, R.
    Levin, W.
    El-Khoueiry, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 180 - 180
  • [37] A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors
    Calvo, E.
    Edelman, G.
    Baselga, J.
    Kwak, E.
    Scheffold, C.
    Nguyen, L.
    Shapiro, G. I.
    EJC SUPPLEMENTS, 2008, 6 (12): : 69 - 69
  • [38] Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors
    Lickliter, Jason D.
    Jennens, Ross
    Lemech, Charlotte Rose
    Su, Steven Yung-Chang
    Chen, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
    Jordan Berlin
    Ramesh K. Ramanathan
    John H. Strickler
    Deepa S. Subramaniam
    John Marshall
    Yoon-Koo Kang
    Robert Hetman
    Matthew W. Dudley
    Jiewei Zeng
    Caroline Nickner
    Hao Xiong
    Philip Komarnitsky
    Stacie Peacock Shepherd
    Herbert Hurwitz
    Heinz-Josef Lenz
    British Journal of Cancer, 2018, 118 : 938 - 946
  • [40] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
    Berlin, Jordan
    Ramanathan, Ramesh K.
    Strickler, John H.
    Subramaniam, Deepa S.
    Marshall, John
    Kang, Yoon-Koo
    Hetman, Robert
    Dudley, Matthew W.
    Zeng, Jiewei
    Nickner, Caroline
    Xiong, Hao
    Komarnitsky, Philip
    Shepherd, Stacie Peacock
    Hurwitz, Herbert
    Lenz, Heinz-Josef
    BRITISH JOURNAL OF CANCER, 2018, 118 (07) : 938 - 946
12345